



Pneumococcal Vaccines

Katherine A. Poehling, MD, MPH

Pneumococcal Vaccines Work Group Chair

Advisory Committee on Immunization Practices

January 12, 2022

Pneumococcal Vaccines Work Group

- **ACIP Members**

- Katherine Poehling (Chair)
- Sarah Long

- **Ex Officio Members**

- Jeffrey Kelman (CMS)
- Lucia Lee (FDA)
- Tina Mongeau (FDA)
- Uzo Chukwuma (IHS)
- Mamodikoe Makhene (NIH)

- **CDC Lead**

- Miwako Kobayashi (NCIRD)

- **Liaison Representatives and Consultants**

- Lynn Fisher (AAFP)
- Mark Sawyer (AAP/COID)
- Jason Goldman (ACP)
- David Nace (AGS/AMDA)
- Emily Messerli (AIM)
- Elissa Abrams (NACI)
- Carol Baker (IDSA)
- William Schaffner (NFID)
- Virginia Caine (NMA)
- Monica Farley (VAMC/Emory)
- Keith Klugman (BMGF)
- Arthur Reingold (UC Berkley)
- Lorry Rubin (CCMC)
- Cynthia Whitney (Emory)
- Richard Zimmerman (U. of Pittsburgh)

Pneumococcal Vaccines Work Group

- **CDC Contributors**

- Adam Cohen (Respiratory Diseases Branch)
- Tamara Pilishvili (Respiratory Diseases Branch)
- Ryan Gierke (Respiratory Diseases Branch)
- Jennifer Farrar (Respiratory Diseases Branch)
- Pedro Moro (Immunization Safety Office)
- Sarah Schillie (Immunization Services Division)
- Marc Fischer (Arctic Investigations Program)
- Jessica MacNeil (ACIP Secretariat)

- **GRADE/EtR consultants**

- Doug Campos-Outcalt
- Rebecca Morgan

Pneumococcal Vaccines Work Group Terms of Reference

- Review current data including efficacy, effectiveness, immunogenicity, epidemiology, and cost-effectiveness of pneumococcal vaccines and assess the strength of the evidence
- Review current recommendations considering up-to-date evidence
- Revise or update recommendations for pneumococcal vaccine use as needed

October 2021 ACIP Vote on Use of PCV15/PCV20

Adults aged ≥ 65 years **who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown** should receive a dose of pneumococcal conjugate vaccine (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23.

October 2021 ACIP Vote on Use of PCV15/PCV20

Adults aged 19–64 years with certain underlying medical conditions or other risk factors* **who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown** should receive a dose of pneumococcal conjugate vaccine (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23.

*Alcoholism, chronic heart/liver/lung disease, diabetes, cigarette smoking, chronic renal failure, nephrotic syndrome, immunodeficiency, iatrogenic immunosuppression, generalized malignancy, human immunodeficiency virus infection, Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplants, congenital or acquired asplenia, sickle cell disease, or other hemoglobinopathies, CSF leak, or cochlear implant

Anticipated timeline of PCV15 and PCV20 licensure in children

